ATORVASTATIN CALCIUM tablet

Land: USA

Språk: engelsk

Kilde: NLM (National Library of Medicine)

Kjøp det nå

Last ned Preparatomtale (SPC)
12-11-2021

Aktiv ingrediens:

ATORVASTATIN CALCIUM TRIHYDRATE (UNII: 48A5M73Z4Q) (ATORVASTATIN - UNII:A0JWA85V8F)

Tilgjengelig fra:

Mckesson Corporation DBA SKY Packaginng

Administreringsrute:

ORAL

Resept typen:

PRESCRIPTION DRUG

Indikasjoner:

Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to:  - Reduce the risk of myocardial infarction     - Reduce the risk of stroke     - Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary hear

Produkt oppsummering:

Atorvastatin calcium tablets USP, 10 mg are white to off-white, capsule shaped, biconvex, film coated tablets debossed ‘RDY’ on one side and ‘121’ on other side and are supplied in: Boxes of 10x10 UD 100, NDC 63739-018-10 Atorvastatin calcium tablets USP, 20 mg are white to off-white, capsule shaped, biconvex, film coated tablets debossed ‘RDY’ on one side and ‘122’ on other side and are supplied in: Boxes of 10x10 UD 100, NDC 63739-020-10 Atorvastatin calcium tablets USP, 40 mg are white to off-white, capsule shaped, biconvex, film coated tablets debossed ‘RDY’ on one side and ‘123’ on other side and are supplied in: Boxes of 10x10 UD 100, NDC 63739-036-10

Autorisasjon status:

Abbreviated New Drug Application

Preparatomtale

                                ATORVASTATIN CALCIUM- ATORVASTATIN CALCIUM TABLET
MCKESSON CORPORATION DBA SKY PACKAGINNG
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
ATORVASTATIN CALCIUM
TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
ATORVASTATIN CALCIUM
TABLETS.
ATORVASTATIN CALCIUM TABLETS, FOR ORAL ADMINISTRATION
INITIAL U.S. APPROVAL: 1996
RECENT MAJOR CHANGES
Dosage and Administration, Dosage in Patients Taking Cyclosporine,
Clarithromycin, Itraconazole,
Letermovir, or Certain Protease Inhibitors (2.6) 11/2019
Warnings and Precautions, Skeletal Muscle (5.1) 11/2019
INDICATIONS AND USAGE
Atorvastatin calcium tablet is an HMG-CoA reductase inhibitor
indicated as an adjunct therapy to diet to:
Reduce the risk of MI, stroke, revascularization procedures, and
angina in adult patients without CHD,
but with multiple risk factors ( 1.1).
Reduce the risk of MI and stroke in adult patients with type 2
diabetes without CHD, but with multiple
risk factors (1.1). · Reduce the risk of non-fatal MI, fatal and
non-fatal stroke, revascularization
procedures, hospitalization for CHF, and angina in adult patients with
CHD ( 1.1).
Reduce elevated total-C, LDL-C, apo B, and TG levels and increase
HDL-C in adult patients with primary
hyperlipidemia (heterozygous familial and nonfamilial) and mixed
dyslipidemia ( 1.2).
Reduce elevated TG in adult patients with hypertriglyceridemia and
primary dysbetalipoproteinemia (
1.2).
Reduce total-C and LDL-C in patients with homozygous familial
hypercholesterolemia (HoFH) ( 1.2).
Reduce elevated total-C, LDL-C, and apo B levels in pediatric
patients, 10 years to 17 years of age, with
heterozygous familial hypercholesterolemia (HeFH) after failing an
adequate trial of diet therapy ( 1.2).
Limitations of Use:
Atorvastatin calcium tablets have not been studied in Fredrickson
Types I and V dyslipidemias ( 1.3).
DOSAGE AND ADMINISTRATION
Dose range: 10 to 80 mg once daily ( 2.1).
Recommended start dose: 10 or 20 mg once daily ( 2.1).
P
                                
                                Les hele dokumentet
                                
                            

Søk varsler relatert til dette produktet